Mark O’Mahony
Net worth: 16 253 $ as of 2026-07-30
Net worth: 16 253 $ as of 2026-07-30
Mark O’Mahony formerly worked at Millennium Pharmaceuticals, Inc., as Principal in 2000, LeukoSite, Inc., as Principal in 2000, Tolerx, Inc., as VP-Process Development & Manufacturing from 2000 to 2011, DecImmune Therapeutics, Inc., as Vice President-Manufacturing & Quality, Serono Corp., as Principal, and Leap Therapeutics, Inc., as Vice President-Manufacturing from 2011 to 2020.
Mr. O’Mahony received his Masters Business Admin degree from Boston University and undergraduate degree from University College Dublin.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2025-03-27 | 27,500 ( 0.03% ) | 16 253 $ | 2026-07-30 |
| Companies | Position | End |
|---|---|---|
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Manufactures biopharmaceutical products | Corporate Officer/Principal | 2011-12-18 |
LeukoSite, Inc.
LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of cancer and inflammatory diseases | Corporate Officer/Principal | 1999-12-31 |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Corporate Officer/Principal | 1999-12-31 |
| CYPHERPUNK TECHNOLOGIES INC. | Corporate Officer/Principal | - |
DecImmune Therapeutics, Inc.
DecImmune Therapeutics, Inc. BiotechnologyHealth Technology Develops novel peptides and antibodies for acute and tissue damaging inflammation | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 8 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Health Technology |
LeukoSite, Inc.
LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of cancer and inflammatory diseases | Health Technology |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Manufactures biopharmaceutical products | Health Technology |
DecImmune Therapeutics, Inc.
DecImmune Therapeutics, Inc. BiotechnologyHealth Technology Develops novel peptides and antibodies for acute and tissue damaging inflammation | Health Technology |
Boston University
Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University College Dublin
University College Dublin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Serono Corp. | |
Leap Therapeutics, Inc.
Leap Therapeutics, Inc. BiotechnologyHealth Technology Engages in clinical stage immuno-oncology | Health Technology |
Select your edition
All financial news and data tailored to specific country editions